Insider · CIK 0001421930
David J Moss
Files at INMB (Inmune Bio, Inc.). First filing -, latest -.
In brief
David J Moss files SEC Form 4 as CFO, 10% owner, CEO and director at INMB (Inmune Bio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; David J Moss has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | INMB Inmune Bio, Inc. | MOption exercise Common Stock | +9,014 | $1.40 | $13k | 1,294,883 | Jul 7, 2026 |
| Jul 2, 2026 | INMB Inmune Bio, Inc. | XIn-the-money exercise Common Stock Purchase Warrantderivative | -9,014 | $0.13 | $1,127 | 9,014 | Jul 7, 2026 |
| Dec 1, 2025 | INMB Inmune Bio, Inc. | AGrant or award Option (right to buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Dec 2, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -400,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +400,000 | - | - | 400,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -59,337 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +59,337 | - | - | 59,337 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -275,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +275,000 | - | - | 275,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -70,663 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +70,663 | - | - | 70,663 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -160,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +160,000 | - | - | 160,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -130,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +130,000 | - | - | 130,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -223,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +223,000 | - | - | 223,000 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -160,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | INMB Inmune Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +160,000 | - | - | 160,000 | Nov 18, 2025 |
| Dec 5, 2024 | INMB Inmune Bio, Inc. | AGrant or award Option (right to buy)derivative | +223,000 | $0.00 | $0 | 223,000 | Dec 9, 2024 |
Questions about David J Moss
Answered from the filings on this page, as of the latest one.
Is David J Moss buying or selling?
David J Moss has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did David J Moss's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David J Moss has 0.
Where does David J Moss file Form 4?
David J Moss has filed Form 4 at INMB (Inmune Bio, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.